In the past six months, drug price cuts continued to reverberate across the Asia-Pacific. Major countries such as China, India and Australia announced further drug price reductions. Leading Asian drugmakers posted a mixed bag of earnings. Takeda Pharmaceutical (TSE: 4502) and Dr Reddy’s Laboratories (BSE: 500124) for example, posted double-digit declines in net profit while others such as Lupin Ltd (NYSE: MYL) saw significant growth as its profits rose more than 40% year-on-year due to strong sales growth in their US market. The shares prices of 11 leading Asian pharmaceutical companies posted average gains of approximately 22% over the six-month period under review from September 4, 2012, to February 26, 2013. Ten out of the 11 companies assessed by Mergent saw their share prices rise over the period, with Dainippon Sumitomo Pharma’s stock price rising the most at nearly 58%. In the past six months, pharmaceutical merger and acquisition activity in the region somewhat slowed down, compared to the strong level of merger and acquisition activity (M&A) seen in the first half of 2012.

随着经济实力加强和全球经济一体化的实现，我国原料药的生产和出口比重也越来越大，在世界原料药是市场中占据了举足轻重的地位，是原料药生产和出口的大国。但是，我国原料药的出口仍然要面对很多贸易上的考验和难关，并且，金融危机和全球经济的缓慢复苏也给我国原料药的出口带来了巨大的挑战。本文主要从经济学和国际贸易和管理学的角度出发，主要阐述了我国医药企业原料药的国内外市场现状、市场优势和面临挑战以及应当采取的战略对策。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从医药行业安邦视点、政策环境、市场行情、厂商动态、科技研发、国际资讯、行业数据、分析评论等几个方面进行了分析及评论。

The Asia-Pacific biotech industry remained one of the fastest emerging knowledge-based industries in the region over the last six months. Several leading companies reported higher revenues, while an average of the stock prices of companies tracked by Mergent rose 4.07% over the six-month period. Due to economic challenges in several major markets, a steady number of foreign biotech and pharmaceutical companies, particularly from North America and Europe, shifted their focus to markets in the Asia-Pacific. The industry also saw several cross-border mergers and acquisitions (M&A) as biotech companies sought to obtain the benefits of various fiscal incentives in other nations and regions.